Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microplasmin in Acute Peripheral Arterial Occlusion
NCT00123292Phase 2Terminated
- Sponsor
- Oxurion
- Start
- Mar 2005
- Primary completion
- Jun 2007
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ocriplasmin in peripheral arterial occlusion (PAO) (5 arms), sponsored by Oxurion. Primary endpoint: Complete clot-lysis at 4 hours. Started Mar 2005; status: terminated.
02
Drugs
ocriplasmin
03
Conditions
peripheral arterial occlusion (PAO)
Beyond the preview
Go deeper on NCT00123292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123292.